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that PDT may be an effective adjuvant for therapies that 
fail to stimulate the host anti-tumor immune response.
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Abbreviations
CTL  Cytotoxic T lymphocyte
CSFE  Carboxyfluorescein triacetate, succinimidyl ester
DAMP  Damage-associated pattern protein
HA  Hemagglutinin
HPPH  2-[1-Hexyloxyethyl]-2-devinyl 
pyropheophorbide-a
IACUC  Institute Animal Care and Use Committee
MHC  Major histocompatibility complex
PDT  Photodynamic therapy
PII  Sodium Porfimer
TDLN  Tumor-draining lymph node
Introduction
Cancer is a multi-faceted disease, and although therapeu-
tic outcomes have improved over the decades and single 
treatment modalities are generally effective at controlling 
the primary tumor, they have little effect on distant disease. 
This has led to the development of combination therapies 
that strive to both control primary tumor growth and acti-
vate the host immune system to combat distant disease. 
Photodynamic therapy (PDT) is an FDA-approved anti-
cancer modality used for treatment of early stage disease 
and palliation of advanced disease [1]. Treatment is carried 
out by systemic administration of a photosensitizer that 
is activated locally with tissue-penetrating visible light, 
resulting in tumor destruction via oxygen-dependent direct 
Abstract Effective therapy for advanced cancer often 
requires treatment of both primary tumors and systemic 
disease that may not be apparent at initial diagnosis. 
Numerous studies have shown that stimulation of the host 
immune system can result in the generation of anti-tumor 
immune responses capable of controlling metastatic tumor 
growth. Thus, there is interest in the development of com-
bination therapies that both control primary tumor growth 
and stimulate anti-tumor immunity for control of metastatic 
disease and subsequent tumor growth. Photodynamic ther-
apy (PDT) is an FDA-approved anticancer modality that 
has been shown to enhance anti-tumor immunity. Augmen-
tation of anti-tumor immunity by PDT is regimen depend-
ent, and PDT regimens that enhance anti-tumor immunity 
have been defined. Unfortunately, these regimens have 
limited ability to control primary tumor growth. There-
fore, a two-step combination therapy was devised in which 
a tumor-controlling PDT regimen was combined with an 
immune-enhancing PDT regimen. To determine whether 
the two-step combination therapy enhanced anti-tumor 
immunity, resistance to subsequent tumor challenge and 
T cell activation and function was measured. The ability 
to control distant disease was also determined. The results 
showed that the novel combination therapy stimulated anti-
tumor immunity while retaining the ability to inhibit pri-
mary tumor growth of both murine colon (Colon26-HA) 
and mammary (4T1) carcinomas. The combination therapy 
resulted in enhanced tumor-specific T cell activation and 
controlled metastatic tumor growth. These results suggest 
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tumor cell cytotoxicity, vascular damage, and the initiation 
of acute local and systemic inflammation. The photosensi-
tizer dose, light dose, and light dose-rate define the PDT 
regimen [2]. Numerous preclinical and clinical studies have 
shown that PDT efficacy is dependent upon the presence of 
an intact immune system [1] and that certain PDT regimens 
can enhance anti-tumor immunity [3, 4].
PDT-enhanced anti-tumor immunity is mediated by 
CD8+ cytotoxic T cells (CTLs) [3, 4] and is accompanied 
by enhanced CTL-mediated tumor cytotoxicity, formation 
of immune memory cells, and resistance to subsequent 
tumor growth [5]. CD8+ T cell depletion or tumor cell loss 
of molecules needed for CD8+ T cell recognition [major 
histocompatibility complex (MHC) class I molecules] 
result in reduced PDT efficacy [5–7]. PDT-activated CD8+ 
T cells also play a critical role in PDT-mediated control of 
secondary disease [8]. PDT enhancement of CTL activation 
and anti-tumor immunity is dependent upon induction of 
acute inflammation [5].
PDT-induced acute inflammation is characterized by 
rapid migration of neutrophils into the treated tumor bed 
and tumor-draining lymph nodes and enhanced expression 
of pro-inflammatory chemokines and cytokines [9, 10]. The 
degree of acute inflammation induced by PDT is regimen 
dependent and correlates with the degree of vascular dam-
age induced [2]. Henderson et al. [2] demonstrated that 
PDT regimens that result in rapid cell death (within 1 h 
of treatment) and maximal tissue damage cause minimal 
acute inflammation, presumably because of vascular shut 
down, which prevents neutrophil infiltration and systemic 
release of cytokines. In contrast, regimens that cause dif-
fuse tumor damage permit neutrophil infiltration and allow 
for expression and release of inflammatory mediators criti-
cal for enhancement of anti-tumor immunity. However, the 
diffuse tumor damage caused by these regimens resulted in 
less effective long-term tumor control.
Combination therapies take advantage of the comple-
mentary action of the individual components, thereby 
potentiating the therapeutic effect. We hypothesized that it 
would be possible to devise a PDT-only therapy using dis-
tinctly different, but complimentary, treatment regimens 
that in combination would enhanced anti-tumor immu-
nity as well as provide effective control of primary tumor 
growth. To test this hypothesis, we devised a multi-step 
local treatment program that was comprised of an immune-
enhancing PDT regimen followed by a tumor ablation PDT 
regimen. Results presented here demonstrate that this pro-
gram was able to control the growth of murine colon and 
mammary tumors and to promote anti-tumor immunity that 
was effective against distant disease. These studies dem-
onstrate that PDT-only therapies can be developed that are 
effective as both a local therapy for control of primary dis-
ease and a systemic therapy for treatment of distant disease.
Materials and methods
Animals and tumor system
Pathogen-free BALB/c mice were obtained from the NCI; 
scid mice were obtained from the Roswell Park Department 
of Laboratory Animal Resources. All mice were female, of 
BALB/c background, and were housed in microisolator 
cages in a laminar flow unit under ambient light. Six- to 
ten-week-old animals were inoculated subcutaneously on 
either the right shoulder with 106 Colo26 (murine colon 
carcinoma) or Colo26 cells transfected with hemagglutinin 
(HA) cDNA (Colo26-HA; [11]) or in the mammary fat pad 
with 5 × 105 4T1 mammary carcinoma cells. Intravenous 
challenge with tumor cells was performed by injection of 
exponentially growing tumor cells. The Roswell Park Can-
cer Institutional Animal Care and Use Committee (IACUC) 
approved all procedures carried out in this study.
Reagents
Clinical-grade, pyrogen-free 2-[1-hexyloxyethyl]-2-devinyl 
pyropheophorbide-a (HPPH) was obtained from the Roswell 
Park Pharmacy (Buffalo, NY) and reconstituted to 0.4 μM 
in pyrogen-free 5 % dextrose in water (D5W; Baxter Corp., 
Deerfield, IL). Porfimer sodium (PII) was obtained from Pin-
nacle Biologics (Bannockburn, IL) and reconstituted in D5W.
In vivo PDT treatment
Tumor-bearing mice were injected in the tail vein with 
0.4 μmol/kg HPPH or 5 mg/kg PII, followed 18–24 h later 
by illumination to a total light dose of 48 J/cm2 or 132 J/cm2 
delivered at a light dose-rate of 14 mW/cm2 as previously 
described [2, 5]. Control mice were treated with photosensi-
tizer or light alone. Mice receiving a combination PDT regi-
men were treated initially with 0.4 μmol/kg HPPH or 5 mg/
kg PII followed 18–24 h later by light dose of 48 J/cm2 
given at 14 mW/cm2; 9 days later, mice were again injected 
with photosensitizer and tumors were illuminated with light 
at a dose of 132 J/cm2 given at 14 mW/cm2.
Transmission of PDT-activating light through tumor tissue
Noninvasive reflectance spectroscopy was used to measure 
the penetration of 665-nm light through subcutaneously 
implanted Colo26-HA tumors. Light attenuation was deter-
mined as previously described [12–15]. Briefly, the diffuse 
fluence Φ at 665 nm was measured at increasing probe sep-
arations. The total attenuation α is the slope of ln(rΦ) plot-
ted against r, where r is the probe separation in mm and Φ 
is the diffuse 665 nm fluence escaping from the tumor at r 
mm from the light source fiber.
289Cancer Immunol Immunother (2015) 64:287–297 
1 3
Tumor response determination
Following treatment, orthogonal diameters of tumors 
were measured once every 2 days with calipers as previ-
ously described [2]. Animals were considered cured if they 
remained tumor free for 60 days after PDT. Treatment with 
light alone, at either dose, had no effect on the growth of 
Colo26-HA or 4T1 tumors.
Flow cytometry
Auxiliary tumor-draining lymph nodes (TDLNs) or tumors 
were harvested at the indicated time points, and single cell 
suspensions were generated [16]. Cells were stained with a 
panel of monoclonal antibodies (MAbs) to detect specific 
cell surface antigens (CD8, CD11b, CD25, CD44, CD45, 
CD69, Ly6C, and Ly6G), as previously described [16]. At 
least five mice per group were analyzed. For the determi-
nation of the absolute number of specific cell populations, 
the percentage of each population was multiplied by the 
number of cells recovered from the respective TDLN or 
tumor.
In Vivo cytotoxicity assay
In vivo cytotoxic assays were performed as previously 
described [17]. Briefly, TDLNs were harvested from 
treated mice 2 days post-PDT and adoptively transferred 
into naive BALB/c hosts as previously described [5]. 
Red blood cell depleted spleen cells isolated from naïve 
mice were used as target cells for the assay. Target cells 
were prepared by labeling a single cell suspension with 
PKH26 dye (Sigma, St. Louis, MO) for 4 min at 2 μM 
according to the manufacturer’s instructions. The result-
ing red population was separated in two equal fractions 
one of which was labeled with 0.1 µM carboxyfluores-
cein triacetate, succinimidyl ester (CFDA-SE, referred 
to as CFSE, Molecular Probes) and the other with 1 µM 
CFSE for 2 min. The lower-intensity-labeled fraction 
was pulsed for 1.5 h with an irrelevant peptide PA1 [18]; 
the high-intensity-labeled fraction was pulsed with the 
Colo26-specific peptide AH1 [19]. Equal cell numbers 
from both populations were admixed and injected into 
recipient mice. Twenty-four hours later peripheral blood 
was collected, RBC were lysed, cells were fixed, and then 
run on a FACS Calibur flow cytometer. Target cells were 
distinguished from host cells based on PKH26 staining; 
PA1 peptide- and AH1 peptide-loaded cells were distin-
guished from one another based on CFSE staining. Gat-
ing on PKH26+ cells, specific cytotoxicity was calculated 






% positive PA1 cells
])
× 100 %.
Assessment of lung tumor growth
4T1 tumor-bearing mice were treated with PII; 18 h fol-
lowing PII injection, tumors were treated with immune-
enhancing PDT. After 9 days, tumors that had been treated 
with immune-enhancing PDT regimens were either sur-
gically removed or treated with tumor-controlling PDT. 
Tumors at an equivalent size to those treated 9 days fol-
lowing the immune-enhancing PDT regimen were treated 
with PII alone, surgically removed or treated with the 
tumor-controlling PDT regimen. Fourteen days after the 
final treatment, the presence of tumors was determined by 
injection of 1 ml of 15 % India ink (diluted in PBS) which 
was injected via an incision in the trachea. The lungs were 
removed from the rib cage, weighed, and placed in Fekete’s 
fixative (61 % ethanol, 3.2 % formaldehyde, 4.1 % acetic 
acid); lung tumors were counted under a dissecting micro-
scope [20].
Statistical evaluation
All measured values are presented as mean ± SEM. Stu-
dent’s t test with Welch’s correction was used for com-
parison between groups in all of the experiments, with 
the exception of tumor response experiments, which were 
analyzed using Log-rank (Mantel-Cox) analysis of survival 
curves. The term “significant” in the text represents a P 
value equal to or less than 0.05.
Results
Long-term tumor growth control following combination 
PDT
Our previous studies indicated that treatment regimens 
that led to optimal long-term tumor response elicited only 
marginal inflammation and limited enhancement of anti-
tumor immunity [2, 5]. These treatment regimens also 
ablated the tumor vasculature, and treated tumors showed 
widespread areas of apoptosis that was accompanied by 
prolonged caspase 3 activation. In contrast, regimens that 
elicited acute inflammation and strong anti-tumor immu-
nity preserved the tumor vasculature, resulted in minimal 
long-term tumor growth control, limited areas of apop-
tosis, and transient caspase 3 activation. Therefore, we 
refer to these treatments as immune enhancing, while 
those regimens that effectively control tumor growth, but 
result in minimal enhancement of anti-tumor immunity, 
are referred to as tumor-controlling regimens. We hypoth-
esized that treating tumors with an immune-enhancing 
PDT regimen followed by a tumor-controlling PDT regi-
men could lead to enhancement of anti-tumor immunity, 
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while retaining effective control of primary tumor growth. 
To test this hypothesis, a combination treatment regimen 
was devised in which Colo26-HA tumor-bearing BALB/c 
mice were treated with a HPPH-PDT regimen known to 
lead to enhanced anti-tumor immunity (0.4 μmoles/kg 
HPPH followed 18 h later by illumination with 665 nm 
light for a total dose of 48 J/cm2 [5]). Following illumina-
tion, mice were rested for 9 days; on the ninth day, mice 
were injected with HPPH. On day 10 following the first 
treatment, tumors were treated with a tumor control treat-
ment regimen (illumination with 665 nm light for a total 
dose of 132 J/cm2 given [5]).
PDT efficacy depends on the intensity and distribution 
of light in the tumor. We were concerned that the initial 
PDT exposure might change the optical properties of the 
tumor tissue and perturb the effectiveness of the subsequent 
PDT exposure. Therefore, we measured light transmission 
through Colo26-HA tumors immediately before both the 
first and the second PDT treatments and compared their 
calculated optical penetration depths (characterized by δ, 
the distance over which diffuse light decreases in inten-
sity to 1/e or 37 % of its initial value) through tumor tis-
sue. Light penetration measured immediately before the 
second PDT treatment was slightly greater than that deter-
mined before the first PDT treatment (δPDT1 = 2.80 mm, 
δPDT2 = 3.06 mm), but that difference was not statistically 
significant. Thus, prior treatment with an immune-enhanc-
ing PDT regimen does not alter the optical properties of the 
tumor tissue.
We next tested whether prior treatment with an immune-
enhancing PDT regimen altered effectiveness of tumor-
controlling PDT regimens. Colo26-HA tumor-bearing 
mice were treated with the combination therapy (immune-
enhancing PDT followed 10 days later with tumor-control-
ling PDT). Animals bearing tumors of an equivalent size to 
the regrowing tumors present in the animals treated initially 
with immune-enhancing PDT at the time of the second 
HPPH injection (9 days following delivery of the initial 
immune-enhancing PDT regimen) were also injected with 
HPPH and were treated 18 h later with the tumor control 
PDT regimen or were treated with 665 nm light for a total 
dose of 48 J/cm2 or 135 J/cm2. Tumor growth was moni-
tored for 60 days (Fig. 1a). All treatments resulted in signif-
icant tumor control when compared to the control treatment 
with either HPPH or light alone (P ≤ 0.001); for simplic-
ity sake, the tumor growth response of tumors treated with 
light alone is not depicted. The combination treatment 
controlled tumor growth as well as the single treatment at 
132 J/cm2 (P ≤ 0.4) and significantly better than treatment 
with 48 J/cm2 (P ≤ 0.001). Thus, demonstrating that prior 
treatment of tumors with an immune-enhancing regimen 
did not affect tumor growth control by the optimal tumor 
growth control treatment regimen.
To determine whether the results obtained were limited 
to a specific photosensitizer, the two-step combination 
therapy was performed using sodium Porfimer (PII) as 
the photosensitizer. Colo26-HA tumor-bearing mice were 
treated as above except that PII (5 mg/kg) was used in 
place of HPPH as the photosensitizer. Colo26-HA tumors 
responded similarly to PII-PDT as they did to HPPH-PDT 
(Fig. 1b). Minimal but significant tumor efficacy was 
observed following treatment with the immune-enhancing 
PII-PDT regimen (48 J/cm2; P ≤ 0.05); treatment with 
either the tumor-controlling PII-PDT treatment regimen 
(132 J/cm2) or the two-step combination therapy resulted 
in increased tumor growth control that was significantly 
Fig. 1  Long-term tumor growth controlfollowing combination ther-
apy. Colo26-HA tumor-bearing mice were injected systemically with 
HPPH (a; 0.4 μmol/kg) or PII (b; 5 mg/kg); 18–24 h later, mice were 
subjected to PDT at a total dose of 48 J/cm2. Nine days later, treated 
mice were randomly divided into two groups. One group was injected 
systemically with HPPH (a; 0.4 μmol/kg) or PII (b; 5 mg/kg); tumor 
growth was monitored in the second group, which represents the 
immune-enhancing treatment group. Control mice bearing Colo26-
HA tumors of equal size to those regrowing in mice that had been 
previously treated with PDT at a dose of 48 J/cm2 were also injected 
systemically with HPPH or PII; 18–24 h later, control mice were 
left untreated (HPPH or PII alone) or treated with PDT (132 J/cm2; 
tumor-controlling regimen). Mice that had been previously treated 
with PDT at a dose of 48 J/cm2 were retreated with PDT at a dose of 
132 J/cm2 (combination). Each group contained a minimum of eight 
animals. Tumor growth was followed until tumors reached 400 mm3 
or 60 days
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greater than that observed with either PII treatment alone 
or treatment with the low-dose PDT regimen (P ≤ 0.003 
or P ≤ 0.04, respectively). There was no significant dif-
ference in tumor growth control between treatment with 
the high-dose PDT regimen and the two-step combination 
therapy.
The two-step combination therapy was also tested in 
the 4T1 mammary carcinoma model. Neutrophil mobili-
zation into tumor tissue is a characteristic of PDT-induced 
acute inflammation [5, 21]; neutrophil mobilization into 
tumor-draining lymph nodes (TDLNs) is required for PDT 
enhancement of anti-tumor immunity [5]. Therefore, neu-
trophil mobilization into tumors and TDLNs was examined 
following PDT of orthotopically growing 4T1 mammary 
carcinomas. 4T1 tumor-bearing mice were treated with PII-
PDT (5 mg/kg PII followed 18 h later by illumination with 
630 nm light for a total dose of either 48 J/cm2 or 132 J/
cm2 delivered at 14 mW cm2); the number of infiltrating 
neutrophils present 4 h post-treatment in the tumor bed 
and TDLN was determined by flow cytometry. Neutrophils 
were identified as those CD45+CD11b+ cells (tumor) or 
CD11b+ cells (TDLN) expressing Ly6C and high levels of 
Ly6G [22]. Treatment of 4T1 tumors with a PII-PDT regi-
men of 48 J/cm2 led to a significant increase in the number 
of neutrophils present in the treated tumor bed (Fig. 2a) and 
TDLN (Fig. 2b) when compared to the number of neutro-
phils present in tumors or TDLN of animals treated with 
PII alone (P ≤ 0.01; P ≤ 0.03, respectively). In contrast, 
treatment with 132 J/cm2 resulted in a negligible increase 
in neutrophils in either the tumor bed or TDLN (P ≤ 0.1). 
Based upon these findings, we have defined the 48 J/cm2 
treatment as immune enhancing.
Fig. 2  Combination therapy increases long-term tumor growth con-
trol. a, b 4T1 tumor-bearing mice were treated with PII-PDT (5 mg/
kg PII) doses of 48 or 132 J/cm2. Control animals were treated with 
PII alone. Each group contained a minimum of five animals. Tumors 
(a) and tumor-draining lymph nodes (TDLN; b) were collected 4 h 
after the final treatment. Single cell suspensions were generated, and 
the number of neutrophils (CD45+CD11b+Ly6C+Ly6GHi)/gm of 
tumor (a) or (CD11b+ Ly6C+Ly6GHi)/TDLN (b) was determined. 
Error bars represent SEM. *P ≤ 0.05; **P ≤ 0.01 (c) 4T1 tumor-
bearing mice were injected systemically with PII (5 mg/kg PII); 
18–24 h later, mice were subjected to PDT at a total dose of 48 J/
cm2. Nine days later, treated mice were randomly divided into two 
groups. One group was injected systemically with PII (5 mg/kg); 
tumor growth was monitored in the second group, which represents 
the immune-enhancing treatment group. Control mice bearing 4T1 
tumors of equal size to those regrowing in mice that had been pre-
viously treated with PDT at a dose of 48 J/cm2 were also injected 
systemically with PII; 18–24 h later, control mice were left untreated 
(PII alone) or treated with PDT (132 J/cm2; tumor-controlling regi-
men). Mice that had been previously treated with PDT at a dose of 
48 J/cm2 were retreated with PDT at a dose of 132 J/cm2 (combi-
nation). Each group contained a minimum of eight animals. Tumor 
growth was followed until tumors reached 400 mm3 or 60 days
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1 3
We then examined the effect of PDT regimens on 4T1 
tumor growth. 4T1 tumor-bearing mice were treated as 
above with PII alone, light alone (630 nm for a total 
dose of 48 J/cm2 or 135 J/cm2 delivered at 14 mW/cm2) 
or PII-PDT (5 mg/kg PII followed 18 h later by illumi-
nation with 630 nm light for a total dose of either 48 J/
cm2 or 132 J/cm2), or with a two-step combination ther-
apy in which 4T1 tumor-bearing mice were treated with 
immune-enhancing PDT followed 10 days later with 
treatment with the higher-dose PDT regimen (5 mg/
kg PII given 9 days after the first treatment, followed 
18–24 h later with illumination with 630 nm light for a 
total dose of 132 J/cm2 delivered at 14 mW cm2). Tumor 
growth following treatment was monitored for 60 days 
or until the primary tumor reached 400 mm3. Treatment 
of 4T1 tumors with the immune-enhancing PII-PDT 
regimen did not lead to long-term tumor growth control 
(P ≥ 0.05 compared to treatment with PII alone); treat-
ment with 132 J/cm2 resulted in marginal, but significant 
control of tumor growth (P ≤ 0.05; Fig. 2c). This was the 
optimal tumor growth control achieved when the fluence 
rate was held to 14 mW/cm2 (data not shown). Therefore, 
the 132 J/cm2 treatment was identified as tumor control-
ling. Interestingly, when the treatments were combined, 
there was a significant increase in long-term tumor 
growth control as compared to treatment with 132 J/cm2 
(P ≤ 0.05).
Combination PDT regimen leads to enhanced anti-tumor T 
cell activation and activity
Previous studies have shown that activated T cells are sus-
ceptible to PDT [23], and it is possible that T cells activated 
in response to immune-enhancing PDT regimens would 
be deleted by subsequent PDT regimens. Therefore, we 
examined the effect of the combination PDT regimen on 
T cell activation. Colo26-HA tumor-bearing BALB/c mice 
were treated with immune-enhancing, tumor-controlling 
or combination PDT regimens. Two days following the 
final treatment, tumor-draining lymph node (TDLN) cells 
were examined by flow cytometry for the presence of acti-
vated, proliferating CD8+ T cells, which were defined as 
CD8+ cells that express CD25 and high levels of CD44. As 
observed previously [5], treatment of Colo26-HA tumors 
with immune-enhancing PDT regimen resulted in signifi-
cantly increased numbers of activated and proliferating 
CD8+ T cells (P ≤ 0.01), while treatment with the tumor-
controlling PDT regimen had minimal effect on the num-
bers of activated CD8+ T cells compared to CD8+ T cells 
isolated from animals treated with HPPH alone (P ≤ 0.2; 
Fig. 3a). Treatment with the combination therapy also led 
to significantly increased numbers of activated, proliferat-
ing CD8+ T cells compared to either CD8+ T cells isolated 
from animals treated with HPPH or tumor-controlling PDT 
(P ≤ 0.01); the increase in activated, proliferating CD8+ 
Fig. 3  Combination therapy increases T cell activation. Colon26-HA 
tumor-bearing mice were treated with HPPH or HPPH-PDT (0.47 
μmoles/kg HPPH) immune-enhancing (48 J/cm2), tumor-controlling 
(132 J/cm2) or a combination regimen of immune-enhancing treat-
ment followed by tumor-controlling treatment as described in Fig. 1. 
a TDLNs were collected 24 h after the final treatment, and single cell 
suspensions were generated. The number of activated CD8+ T cells 
(CD3+CD8+CD44HiCD25+) was determined by flow cytometry. A 
minimum of 14 mice were examined in each group. b TDLNs were 
collected 24 h after the final treatment, and in vivo cytotoxicity assays 
were performed as described in Materials and Methods. Results are 
presented as % specific cytotoxicity. Each symbol represents results 
obtained from an individual mouse; horizontal lines represent the 
median. A minimum of ten mice were examined per group
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T cells following the combination therapy was not signifi-
cantly different from the increase induced by the immune-
enhancing PDT regimen (P ≤ 0.2). Similar results were 
obtained following treatment of 4T1 tumor-bearing mice 
(data not shown).
We have previously demonstrated that the increased 
number of activated and proliferating T cells following 
treatment of Colo26-HA tumor with immune-enhancing 
PDT regimens leads to increased lysis of target cells loaded 
with peptides derived from either the surrogate antigen, 
HA, or gp70, an endogenous tumor antigen expressed by 
Colo26-HA and the parental Colo26 tumor cell lines [5, 
19]. To determine whether the increase in CD8+ T cell 
accumulation observed following the combination treat-
ment was also associated with increase cell lysis, the ability 
of PDT-activated lymph node cells to eliminate target cells 
loaded with tumor-associated peptides was measured in 
vivo. TDLN cells were harvested from treated mice 2 days 
following the last PDT treatment and adoptively transferred 
into naïve BALB/c mice. Recipient mice were then chal-
lenged with an i.v. injection of cells primed with AH1 pep-
tide, which is the immunodominant peptide from gp70 [19] 
or a control peptide. Recipient mice adoptively transferred 
with TDLN cells isolated from mice treated with immune-
enhancing and combination treatment regimens exhibit 
significantly increased specific cytotoxicity against cells 
bearing tumor-specific peptides when compared to recipi-
ent mice receiving TDLN cells from control mice or mice 
treated with the tumor-controlling PDT regimen (Fig. 3b; 
P ≤ 0.001). As predicted and previously observed, recipient 
mice receiving TDLN cells from mice treated with tumor-
controlling PDT regimens exhibited minimal cytotoxicity 
against cells expressing tumor-specific peptides. The lack 
of a known tumor antigen expressed by 4T1 tumors pre-
vented us from carrying out similar assays in this model.
Combination PDT regimen results in increased resistance 
to tumor challenge
To determine whether increased cytotoxicity against tumor 
antigens translated to increased resistance to tumors, mice 
that remained tumor free for 60 days after the final PDT 
treatment were challenged with Colo26 cells. Colo26 cells 
were used in these experiments rather than Colo26-HA 
cells in order to validate the results obtained from the in 
vivo cytotoxicity experiments (Fig. 3b) and to further con-
firm that PDT enhancement of anti-tumor immunity was 
not restricted to immunity against over-expressed surro-
gate antigens as was demonstrated by Mroz et al. [24]. We 
have shown previously that the tumor response of paren-
tal Colo26 tumors and Colo26-HA tumors to HPPH-PDT 
is indistinguishable [5]. Colo26-HA tumor-bearing mice 
that remained tumor free following treatment with either 
immune-enhancing or combination regimens were more 
resistant to subsequent challenge with Colo26 cells than 
mice that remained tumor free following treatment with 
tumor--controlling PDT regimens (P ≤ 0.01; Fig. 4a), con-
firming that enhancement of anti-tumor immunity was not 
solely due to enhanced recognition of the surrogate antigen 
HA. Greater than 60 % of mice treated with the tumor-
controlling PDT regimen remained tumor free for 60 days; 
however, less than 20 % of these mice were able to resist a 
subsequent tumor challenge. Similarly, 4T1 tumor-bearing 
mice whose tumors were eradicated by treatment with the 
combination therapy were better able to resist subsequent 
tumor challenge when compared to mice whose tumors 
were treated with 132 J/cm2 (Fig. 4b; P ≤ 0.01). Since the 
immune-enhancing treatment regimen did not eradicate 
4T1 tumors in any animals, it was not possible to measure 
subsequent resistance to 4T1 tumor challenge in animals 
treated with immune-enhancing PDT regimens.
The increase in effectiveness and anti-tumor immunity 
observed following treatment of 4T1 tumors with the com-
bination therapy suggests that this treatment regimen may 
control metastatic tumor growth. The 4T1 tumor rapidly 
metastasizes to the lung [25]. To assess the effect of PDT 
regimens on metastasis, 4T1 tumor-bearing mice were 
Fig. 4  Combination therapy increases resistance to tumor challenge. 
Colo26-HA or 4T1 tumor-bearing mice were treated with tumor-
controlling, immune-enhancing, or the combination HPPH- or PII-
PDT regimens, respectively, as described in Figs. 1 and 2. Mice that 
remained tumor-free 40 days after treatment were challenged with 
live tumor cells (a: Colon 26 challenge; b: 4T1 challenge). Tumor 
growth was monitored for 60 days or until tumors reached 400 mm3
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treated with immune-enhancing PDT. After 9 days, mice 
that had been treated with immune-enhancing PDT regi-
mens were injected with PII. The following day, previously 
treated tumors were either surgically removed (Immune 
Enhancing + SR) or retreated with tumor-controlling PDT 
(Combination). Tumors at an equivalent size to those pre-
sent in mice treated 10 days prior with the immune-enhanc-
ing PDT regimen were treated with PII alone, surgically 
removed (SR) or treated with the tumor-controlling PDT 
regimen (Tumor Controlling). Lungs were collected from 
the treated and control mice 14 days later, and the number 
of metastases/lung was determined (Fig. 5a).
Neither surgical removal of 4T1 tumors, treatment 
with tumor-controlling PDT, nor treatment with immune-
enhancing PDT regimen followed by surgical removal of 
tumors had a significant effect on the number of tumors 
present in the lung when compared to treatment with PII 
alone. In contrast, treatment with the combination therapy 
significantly reduced the number of tumors present in the 
lung compared to all other treatments tested (P ≤ 0.02).
To determine whether the reduction in lung metastases 
observed following the combination therapy was a result 
of enhanced anti-tumor immunity, the combination treat-
ment was carried out in immune-compromised scid mice 
(Fig. 5b). No significant difference was observed between 
the numbers of lung tumors present in immune-competent 
BALB/c versus the number present in immune-compromised 
scid mice 14 days after surgical removal of the primary 4T1 
tumor or treatment of the primary tumor with either PII 
alone, tumor-controlling PDT, or immune-enhancing PDT 
followed by surgical removal of the primary tumor. How-
ever, surgical removal and treatment of the primary tumor 
with the tumor-controlling PDT regimen did significantly 
reduce the number of lung tumors present in scid mice when 
compared to treatment with PII alone (P ≤ 0.05). Thus, it 
appears as though the reduction in lung tumors observed fol-
lowing surgical removal of the primary tumors or treatment 
of the primary tumors with tumor-controlling PDT was not a 
result of enhanced anti-tumor immunity.
The number of lung tumors present in scid mice was 
significantly higher than those present in BALB/c mice fol-
lowing treatment of primary 4T1 tumors with the combi-
nation PDT regimen (Fig. 5b; P ≤ 0.03); suggesting that 
anti-tumor immunity plays a role in control of metastatic 
tumor growth following treatment. However, the combina-
tion therapy was still able to control metastatic growth in 
the absence of a functioning adaptive immune system as 
the number of lung tumors present in scid mice following 
the combination therapy was significantly lower than the 
number of lung tumors present following surgical removal 
of the primary tumor (P ≤ 0.04) or treatment or the pri-
mary tumor with PII alone (P ≤ 0.0002), tumor-controlling 
Fig. 5  Combination therapy reduces 4T1 lung metastases. 4T1 
tumor-bearing BALB/c (a + b) or scid (b) mice were treated with 
immune-enhancing PDT as described in Fig. 2. After 9 days, treated 
mice were re-injected with PII (5 mg/kg); 18–24 h later tumors were 
either surgically removed (Immune Enhancing + SR) or treated 
with tumor-controlling PDT (combination). Tumors at an equivalent 
size to those present in mice treated 10 days prior with the immune-
enhancing PDT regimen were treated with PII alone, surgically 
removed (SR) or treated with the tumor-controlling PDT regimen 
(tumor controlling). Lungs were collected 14 days later, and the num-
ber of metastases/lung was determined. a Results represent the num-
ber of tumors tumors/mouse. Each symbol represents an individual 
mouse. The mean is represented by a line, and the error bars repre-
sent the SEM. Each group contains a minimum of ten mice. b Results 
represent the average number of lung tumors/mouse. Error bars rep-
resent SEM; each group contains a minimum of ten mice. *P ≤ 0.05, 
**P ≤ 0.001 when compared to treatment with PII alone; #P ≤ 0.05 
when compared to BALB/c
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PDT (P ≤ 0.02), or immune-enhancing PDT followed by 
surgical removal of the primary tumor (P ≤ 0.01).
Discussion
Recent studies have shown that the host response to PDT 
is influenced by the treatment parameters [2] and that treat-
ments of different parameters can be used to in combination 
to achieve desirable outcomes [26]. In the current study, we 
combine an immune-enhancing PDT regimen with a tumor 
growth-controlling PDT regimen in order to develop a single 
modality combination therapy that would both control primary 
tumor growth and stimulate the host immune system to modu-
late growth of distant disease. Treatment of tumor-bearing mice 
with this novel combination therapy resulted in efficacious 
tumor growth control, increased numbers of activated CD8+ 
T cells and tumor-specific cytotoxicity, and an increased in 
resistance to subsequent tumor challenge and metastatic tumor 
growth. Enhancement of anti-tumor immunity by the combi-
nation treatment regimen occurred when either HPPH- or PII-
PDT was used. Additionally, colon and mammary carcinoma 
models exhibited regimen-dependent host responses. This sug-
gests that these findings may be applicable across photosensi-
tizers and that it may be possible to identify immune-enhanc-
ing PDT regimens in multiple tumor models.
The mechanism of the dose-dependent induction of 
inflammation and subsequent enhancement of anti-tumor 
immunity by PDT is unclear. Previous studies by Hender-
son et al. [2] have suggested that treatment of tumors with 
high-dose PDT regimens result in vascular ablation that 
prevents infiltration of the tumor bed by innate immune 
cell and limits acute inflammation. Initiation of inflamma-
tion and subsequent stimulation of anti-tumor immunity 
have been linked to the recognition of alarmins by innate 
immune cells [27, 28]. Alarmins include damage-associ-
ated pattern proteins (DAMPs) and metabolites released 
or expressed on the cell surface by damaged and trans-
formed cells, as well as cytokines such as IL-1α. Alarmins 
are released following PDT and have been linked to gen-
eration of inflammation and anti-tumor immunity [29–32]. 
Recent studies by Tracy et al. [33] have demonstrated that 
PDT dose influences the release of alarmins. Significantly 
at high doses, in vitro PDT treatment of tumor cells leads 
to an inactivation of alarmins and a reduction in the release 
of inflammatory mediators by stromal cells. In contrast, 
Garg et al. [34] showed that expression of a cell surface-
associated DAMP, calreticulin, increased with PDT dose; 
however, the ability of ecto-calreticulin induced by high-
dose PDT to induce inflammation was not tested.
Once activated in the lymph node, CD8+ T cells become 
either effector or memory cells [35]. Effector cells leave the 
lymph node and migrate to the tumor site [36]; memory cells 
migrate to secondary lymphoid organs (central memory T 
cells) or non-lymphoid tissues (effector memory T cells) [36, 
37]. We have previously shown that there is an increase in 
activated tumor-specific CD8+ T cells in the treated tumor 
bed 7 days after treatment with the immune-enhancing PDT 
regimen [5]. Activated, proliferating T cells are susceptible to 
PDT [23]; therefore, it was possible that treatment of tumors 
with a second PDT regimen 10 days after treatment with the 
immune-enhancing PDT regimen would result in elimina-
tion of tumor-specific T cells, which may prevent resistance 
to subsequent tumor challenge. However, mice treated with 
the combination therapy were able to control tumor growth 
when challenged 60 days following treatment, demonstrating 
a persistence of anti-tumor immunity and strongly suggest-
ing the presence of long lived memory T cells.
Importantly, the enhancement of immune reactivity to 
Colo26 tumors by either the immune-enhancing or com-
bination PDT regimens was not limited to recognition of 
an over-expressed surrogate antigen, confirming our previ-
ous preclinical and clinical studies demonstrating that PDT 
enhances immune recognition of endogenous tumor anti-
gens [5, 38]. Similarly, Mroz et al. [39] showed that vascu-
lar PDT regimens enhanced immune reactivity against the 
endogenous cancer/testis antigen PA1; although this treat-
ment regimen was unable to augment anti-tumor immunity 
against endogenous tumor antigens in Colo26 tumors.
Treatment of either the colon or mammary tumor model 
with the combination therapy resulted in effective control 
of primary tumor growth; in the case of the Colo26-HA 
tumor model, there was no significant difference in pri-
mary tumor growth following treatment with the tumor 
growth-controlling PDT regimen and the combination ther-
apy regardless of the photosensitizer used. In contrast, the 
combination therapy controlled primary 4T1 tumor growth 
significantly better than single treatment with the tumor-
controlling PDT regimen. The reason for this difference 
is unclear. One possibility is that although tumor size was 
controlled such that the tumors treated with the single dose 
of tumor-controlling PDT regimen were of similar size to 
those treated 10 days following the immune-controlling 
PDT regimen in the combination therapy, the immune-con-
trolling PDT regimen sensitized the orthotopic tumors to 
PDT in some manner. The immune-controlling PDT regi-
men induces a strong local inflammatory response, which 
could be responsible for this alteration. Studies are cur-
rently underway to address this possibility.
Orthotopic 4T1 tumors rapidly metastasize to the lung 
and liver within 21 days of inoculation [25]. We and oth-
ers have previously shown that PDT-enhanced anti-tumor 
immunity can control distant disease [8, 40–42]. The com-
bination therapy was also able to control 4T1 tumor metas-
tases; although the control was not entirely dependent upon 
the immune system as control was significantly but not 
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completely ablated when the combination therapy was per-
formed in scid mice. Metastatic tumor growth was also par-
tially controlled following surgical removal of the primary 
tumor and treatment with tumor-controlling PDT regimens; 
this control was independent of anti-tumor immunity. The 
number of lung tumors present increases with the size of 
the primary 4T1 and the amount of time the tumor is pre-
sent in the animal [25]. Therefore, it is possible that the 
adaptive immune system-independent reduction in meta-
static tumor growth is due to the absence of the primary 
tumor following surgical removal or treatment-induced 
reduction in primary tumor growth following treatment 
with the tumor growth-controlling PDT regimen.
Our studies support the use of an immune-enhancing 
PDT regimen as an adjuvant treatment that, when used in 
conjunction with therapies that inhibit or do not enhance 
immunity, has the potential to augment anti-tumor immu-
nity. Recent studies have shown that PDT is an effective 
adjuvant therapy to surgery that increases the probability 
of long-term local disease control [1]. Friedberg and col-
leagues have demonstrated prolonged survival in malignant 
pleural mesothelioma patients treated with radical pleurec-
tomy and intraoperative PDT [43] that the authors attribute 
in part to the immune effects of PDT.
In summary, we have identified an anti-tumor combi-
nation PDT treatment regimen that controls primary and 
metastatic tumor growth and enhances anti-tumor immu-
nity. The combination therapy consists of treatment with an 
immune-enhancing PDT regimen followed 10 days later by 
treatment with a tumor growth-controlling treatment regi-
men. Treatment of both colon and mammary carcinomas 
showed similar host responses, and the host responses were 
independent of the photosensitizer used. These findings 
provide proof of principle for the use of PDT as an adju-
vant therapy for enhancement of anti-tumor immunity that 
may be capable of controlling distant disease.
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